Beacon Capital Management LLC Sells 1,120 Shares of Pfizer Inc. (NYSE:PFE)

Beacon Capital Management LLC lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 9.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 11,058 shares of the biopharmaceutical company’s stock after selling 1,120 shares during the quarter. Beacon Capital Management LLC’s holdings in Pfizer were worth $293,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. TigerOak Management L.L.C. bought a new stake in shares of Pfizer during the 4th quarter valued at about $837,000. Roxbury Financial LLC acquired a new position in Pfizer in the fourth quarter valued at approximately $399,000. Manchester Capital Management LLC boosted its holdings in shares of Pfizer by 7.6% during the 4th quarter. Manchester Capital Management LLC now owns 47,137 shares of the biopharmaceutical company’s stock worth $1,251,000 after buying an additional 3,326 shares in the last quarter. BXM Wealth LLC acquired a new stake in shares of Pfizer during the 4th quarter worth approximately $266,000. Finally, Nations Financial Group Inc. IA ADV increased its stake in shares of Pfizer by 64.5% in the 4th quarter. Nations Financial Group Inc. IA ADV now owns 141,049 shares of the biopharmaceutical company’s stock valued at $3,742,000 after acquiring an additional 55,294 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Price Performance

Shares of NYSE:PFE opened at $25.50 on Friday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The stock has a market cap of $144.48 billion, a PE ratio of 18.08, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The stock’s fifty day simple moving average is $26.28 and its two-hundred day simple moving average is $27.58. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same period in the previous year, the company earned $0.10 earnings per share. The firm’s revenue for the quarter was up 24.7% compared to the same quarter last year. As a group, analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a $0.43 dividend. The ex-dividend date is Friday, January 24th. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a dividend yield of 6.75%. Pfizer’s dividend payout ratio is currently 121.99%.

Analysts Set New Price Targets

Several brokerages recently issued reports on PFE. Citigroup cut their target price on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. StockNews.com lowered Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Truist Financial cut their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. Evercore ISI raised Pfizer to a “strong-buy” rating in a research report on Wednesday, October 30th. Finally, Wolfe Research initiated coverage on shares of Pfizer in a research report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price target for the company. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Insider Activity at Pfizer

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of Pfizer stock in a transaction on Thursday, February 13th. The stock was purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the purchase, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.06% of the stock is currently owned by company insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.